Sareum Holdings PLC Results of AGM
December 19 2024 - 10:07AM
RNS Regulatory News
RNS Number : 8213Q
Sareum Holdings PLC
19 December 2024
SAREUM
HOLDINGS PLC
("Sareum"
or the "Company")
Results
of AGM
Cambridge, UK,
19 December 2024 - Sareum Holdings plc
(AIM: SAR), a clinical-stage biotechnology company
developing next-generation kinase inhibitors for autoimmune
disease and cancer, held its Annual
General Meeting ("AGM") today and all resolutions were duly passed.
Voting was conducted by a show of hands and inclusive of votes
received by the Company by way of proxy.
Details of the proxy voting results are shown
in the table below.
|
Ordinary Resolutions
|
Votes For
|
%
|
Votes
Against
|
%
|
Votes Total
|
% of ISC
Voted
|
Votes
Withheld
|
|
1. Receive the financial statements
for the year
|
11,916,088
|
99.38
|
74,805
|
0.62
|
11,990,893
|
9.61%
|
163,189
|
|
2. Receive and
approve the Directors' Renumeration Report for the
year
|
11,800,364
|
98.55
|
174,011
|
1.45
|
11,974,375
|
9.60%
|
179,707
|
|
3. Re-elect Mr
Clive Birch as Director of the Company
|
10,443,572
|
92.12
|
893,439
|
7.88
|
11,337,011
|
9.09%
|
817,071
|
|
4. Re-elect Dr
Michael Owen as Director of the Company
|
10,443,672
|
92.12
|
893,339
|
7.88
|
11,337,011
|
9.09%
|
817,071
|
|
5. Re-appoint
Shipleys LLP as auditor
|
11,775,627
|
98.70
|
154,926
|
1.30
|
11,930,553
|
9.56%
|
223,529
|
|
6. Authorise the audit committee to
determine auditor renumeration
|
11,856,252
|
99.29
|
84,641
|
0.71
|
11,940,893
|
9.57%
|
213,189
|
|
7. Directors'
authority to allot new shares
|
11,538,681
|
96.23
|
451,872
|
3.77
|
11,990,553
|
9.61%
|
163,529
|
|
Special Resolution
|
|
|
|
|
|
|
|
|
8. Directors'
authority to disapply pre-emption rights
|
11,522,085
|
96.30
|
442,974
|
3.70
|
11,965,059
|
9.59%
|
189,023
|
|
9. Authority to hold general
meetings
|
11,893,866
|
99.29
|
84,805
|
0.71
|
11,978,671
|
9.60%
|
175,411
|
The full text of each of the
resolutions is set out in the Notice of AGM, available in the
Investors section of the Company's website
(www.sareum.com/investors)
For further
information, please contact:
|
Sareum Holdings plc
Stephen Parker, Executive
Chaiman
|
01223 497700
ir@sareum.co.uk
|
|
Strand Hanson Limited (Nominated
Adviser)
James Dance / James
Bellman
|
020 7409 3494
|
|
Oberon Capital (Joint
Broker)
Mike Seabrook / Nick
Lovering
|
020 3179 5300
|
|
Hybridan LLP (Joint
Broker)
Claire Noyce
ICR Healthcare (Financial PR)
Jessica Hodgson / Davide Salvi /
Kumail Walijee
|
020 3764 2341
020 3709 5700
|
About
Sareum
Sareum Holdings (AIM:SAR) is a
clinical-stage biotechnology company developing next generation
kinase inhibitors for autoimmune disease and cancer.
The Company is focused on developing
next generation small molecules which modify the activity of the
JAK kinase family and have best-in-class potential. Its lead
candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1.
SDC-1801 is a potential treatment for a range of autoimmune
diseases, including psoriasis, and has completed Phase 1 clinical
development.
Sareum is also developing SDC-1802,
a TYK2/JAK1 inhibitor with a potential application for cancer
immunotherapy.
Sareum Holdings plc is based in
Cambridge, UK, and is listed on the AIM market of the London Stock
Exchange, trading under the ticker SAR. For further information,
please visit the Company's website at
www.sareum.com
- Ends -
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
RAGFLFIRFRLALIS
Sareum (LSE:SAR)
Historical Stock Chart
From Nov 2024 to Dec 2024
Sareum (LSE:SAR)
Historical Stock Chart
From Dec 2023 to Dec 2024
